title: Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
abstract: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, chronic anovulation, polycystic ovaries at ultrasound evaluation, and quite frequently by insulin resistance or compensatory hyperinsulinemia. Attention has been given to the role of inositol-phosphoglycan (IPG) mediators of insulin action and growing evidences suggest that a deficiency of D-chiro-inositol (DCI) containing IPG might be at the basis of insulin resistance, frequent in PCOS patients. On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,. After the treatment interval body mass index (BMI) and insulin resistance decreased together with luteinizing hormone (LH), LH/FSH and insulin. When subdividing the patients according to their fasting insulin levels, Group A (n = 15) insulin below 12 µU/ml and Group B (n = 27) insulin above 12 µU/ml, MYO treatment induced similar changes in both groups but only patients of Group B showed the significant decrease of both fasting insulin plasma levels (from 20.3 ± 1.8 to 12.9 ± 1.8 µU/ml, p < 0.00001) and of area under the curve (AUC) of insulin under oral glucose tolerance test (OGTT). In conclusion, our study supports the hypothesis that MYO administration is more effective in obese patients with high fasting insulin plasma levels.
authors.affiliation: Department of Obstetrics and Gynecology, Center for Gynecological Endocrinology, University of Modena and Reggio Emilia, Modena, Italy. algen@unimo.it
authors.forename: Alessandro D
authors.initials: AD
authors.lastname: Genazzani
authors.forename: Alessia
authors.initials: A
authors.lastname: Prati
authors.forename: Susanna
authors.initials: S
authors.lastname: Santagni
authors.forename: Federica
authors.initials: F
authors.lastname: Ricchieri
authors.forename: Elisa
authors.initials: E
authors.lastname: Chierchia
authors.forename: Erica
authors.initials: E
authors.lastname: Rattighieri
authors.forename: Annalisa
authors.initials: A
authors.lastname: Campedelli
authors.forename: Tommaso
authors.initials: T
authors.lastname: Simoncini
authors.forename: Paolo G
authors.initials: PG
authors.lastname: Artini
mesh_terms: D000328:Adult; D015992:Body Mass Index; D019587:Dietary Supplements; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000097:blood; D005951:Glucose Tolerance Test; D006801:Humans; D006946:Hyperinsulinism / Q000209:etiology / Q000517:prevention & control*; D007294:Inositol / Q000172:deficiency / Q000627:therapeutic use*; D007295:Inositol Phosphates / Q000378:metabolism; D007328:Insulin / Q000097:blood; D007329:Insulin Antagonists / Q000378:metabolism; D007333:Insulin Resistance; D007986:Luteinizing Hormone / Q000097:blood; D009765:Obesity / Q000150:complications*; D050177:Overweight / Q000150:complications*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000178:diet therapy* / Q000378:metabolism / Q000503:physiopathology; D011134:Polysaccharides / Q000378:metabolism; D015431:Weight Loss
chemical_list: D007295:Inositol Phosphates; D007328:Insulin; D007329:Insulin Antagonists; D011134:Polysaccharides; C028039:inositol phosphate glycan; D007294:Inositol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D005492:Folic Acid